logo
  

Eastman Chemical Q4 Adj. Profit Beats View, But Outlook Disappoints

Eastman Chemical Co. (EMN) on Thursday reported a 95 percent plunge in profit for the fourth quarter from last year, as higher revenues were more than offset by one-time charges.

However, adjusted earnings per share for the quarter beat analysts' expectations. Looking ahead, the company forecast earnings for fiscal 2015 below Street estimates.

Kingsport, Tennessee-based Eastman Chemical's fourth-quarter net earnings were $16 million or $0.11 per share, down from $346 million or $2.22 per share in the year-ago period.

The latest quarter's results include a loss of $1.35 per share related to mark-to-market pension and other postretirement benefit plans, additional costs of acquired inventories of $0.07 per share, and acquisition transaction costs of $0.11 per share.

The year-ago period results include, among other items, a gain of $1.15 per share on mark-to-market pension and other postretirement benefit plans.

Excluding items, adjusted earnings for the latest quarter were $1.64 per share, compared to $1.35 per share last year. On average, 15 analysts polled by Thomson Reuters expected the company to report earnings of $1.52 per share for the quarter. Analysts' estimates typically exclude special items.

Sales revenue for the quarter grew 4 percent to $2.35 billion from $2.27 billion in the year-ago period. Analysts had a consensus revenue estimate of $2.34 billion for the quarter.

For fiscal 2014, net earnings attributable to Eastman stockholders declined to $751 million or $4.97 per share from $1.17 billion or $7.44 per share in the prior year. Adjusted earnings from continuing operations were $7.07, compared to $6.44 per share last year.

Sales revenue for the year grew 2 percent to $9.53 billion from $9.35 billion in the previous year.

Street expected the company to earn $6.94 per share for the year on revenues of $9.56 billion.

Looking ahead to fiscal 2015, Eastman Chemical forecast adjusted earnings to be similar to 2014, when it reported $7.07 per share. Analysts expect earnings of $7.45 per share for the year.

Mark Costa, chairman and CEO said, "We enter 2015 well positioned to benefit from our strong portfolio of specialty businesses, including the accretive acquisitions we completed in 2014... In the short-term, we also face challenges including continued global economic uncertainty, volatile oil prices, and the recent strengthening of the U.S. dollar."

In December, Eastman acquired Taminco Corp, a specialty chemical company, and Commonwealth Laminating & Coating Inc, a specialty films business.

EMN closed Thursday's trading at $68.64, down $0.01 or 0.01 percent on a volume of 2.68 million shares. In after-hours, the stock gained $1.36 or 1.98 percent to $70.00.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT